Document is current
Any future updates will be listed below
-
Authors
Cao, Yunlong https://orcid.org/0000-0001-5918-1078
Yisimayi, Ayijiang
Jian, Fanchong https://orcid.org/0000-0001-8703-3507
Song, Weiliang
Xiao, Tianhe
Wang, Lei
Du, Shuo https://orcid.org/0000-0003-0936-0785
Wang, Jing https://orcid.org/0000-0002-9084-9985
Li, Qianqian
Chen, Xiaosu
Yu, Yuanling
Wang, Peng
Zhang, Zhiying https://orcid.org/0000-0002-5690-9796
Liu, Pulan
An, Ran
Hao, Xiaohua
Wang, Yao
Wang, Jing
Feng, Rui
Sun, Haiyan
Zhao, Lijuan
Zhang, Wen
Zhao, Dong
Zheng, Jiang
Yu, Lingling
Li, Can
Zhang, Na
Wang, Rui
Niu, Xiao
Yang, Sijie
Song, Xuetao
Chai, Yangyang
Hu, Ye
Shi, Yansong
Zheng, Linlin
Li, Zhiqiang
Gu, Qingqing
Shao, Fei
Huang, Weijin https://orcid.org/0000-0002-4246-8889
Jin, Ronghua https://orcid.org/0000-0001-8496-172X
Shen, Zhongyang https://orcid.org/0000-0003-0045-4355
Wang, Youchun https://orcid.org/0000-0001-9769-5141
Wang, Xiangxi https://orcid.org/0000-0003-0635-278X
Xiao, Junyu https://orcid.org/0000-0003-1822-1701
Xie, Xiaoliang Sunney https://orcid.org/0000-0001-9281-5239
- License Information
-
More Information
Article History
Received: 30 April 2022
Accepted: 15 June 2022
First Online: 17 June 2022
Competing interests
: X.S.X. and Y. Cao are inventors on the provisional patent applications for BD series antibodies, which includes BD30-604 (DXP-604), BD55-5840 (SA58) and BD55-5514 (SA55). X.S.X. and Y. Cao are founders of Singlomics Biopharmaceuticals. The other authors declare no competing interests.
